New Topical Spray to Help with Premature Ejaculation

I can think of several scenes from various movies where a teenage boy or overeager man has his first or new sexual encounter; the sex lasts all of two minutes and the boy, or man, climaxes leaving the woman unsatisfied and wondering what just happened. My favorite is in a scene with Whitney Houston from Waiting to Exhale where her character is having her first sexual encounter with a new boyfriend. She is talking to herself in her head waiting for her boyfriend to get ready and convincing herself that her “body needs this.” He mounts, climaxes within a minute and rolls off her at which point she thinks to herself annoyingly, “I could have had a V8.”

Now premature ejaculation might be a problem of the past thanks to the development of a topical spray named PSD502. This new spray has been deemed both safe and effective in its treatment of premature ejaculation. The researchers on this study were able to discuss their findings and data on how effective the spray was at the 104th Annual Scientific Meeting of the American Urological Association (AUA).

Up until now, most men who were burdened with premature ejaculations used topical creams which utilized desensitization in order to postpone ejaculation. These creams would dull the skin around the penis; however, they could only be used during foreplay and would need to be washed off or topped with a condom before sexual intercourse began. While effective, many men felt pleasure was reduced significantly with the use of these creams.

Researchers involved in the study of the topical spray note it is also quite effective and simple to use. The spray which includes lidocaine and prilocaine also desensitizes the skin on the penis, but only the foreskin’s inner lining. Because of this limited desensitization, there is no adverse effect on sexual sensation. In order to be effective, this topical spray should be put on approximately five minutes before sexual intercourse.

There were 300 male participants in the study, all who had been diagnosed with premature ejaculation. Diagnosis was determined using the definition used by the International Society of Sexual Medicine (premature ejaculation in less than a minute once intercourse begins). The 300 participants were placed into two separate groups with one group using the new PSD502 topical spray and the other group using a placebo spray. The group that used the PSD502 spray had a vast improvement in latency time, going from an average of 0.6 minutes to four minutes. The placebo group only went up to a latency time of one minute from the same average. Of the group that used the PSD502 spray, there were no serious side effects reported by either participants or their sexual partners. A spokesman for AUA, Ira Sharlip, MD, states, “Premature ejaculation is one of the most common sexual dysfunctions in men. It occurs in 20-30% of men of all ages and we need an effective, patient-friendly treatment for this distressing problem. This new topical spray has promise to become one of the most effective treatments for premature ejaculation. It has a number of characteristics which will be attractive to patients with premature ejaculation.”